Six of 10 pancreatic cancer patients treated with the investigational drug certepetide along with chemotherapy prior to surgery were alive two years later, according…
News
GYNECOLOGICAL CANCER
Corcept seeks European approval of relacorilant for ovarian cancer
Corcept Therapeutics has submitted an application to the European Medicines Agency seeking approval of relacorilant for the treatment of platinum-resistant ovarian cancer. A similar…
Results from a clinical trial testing Exicure‘s therapy candidate burixafor (GPC-100) in stem cell transplants for people with myeloma are expected soon — and the developer…
The Advanced Research Projects Agency for Health (ARPA-H) has awarded up to $48 million to Kernal Bio to support the development of more efficient,…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to an experimental therapy called cintredekin besudotox (IL13-PE38QQR), which Precision Neuromed is…
GYNECOLOGICAL CANCER
Prolactin-raising antipsychotics may increase gynecological cancer risk
Women prescribed antipsychotics that raise the levels of prolactin, a hormone that stimulates milk production and regulates reproductive hormones, had double the rate of…
C4 Therapeutics and Pfizer are teaming up to evaluate whether combining C4’s investigational oral therapy cemsidomide with Pfizer’s approved multiple myeloma treatment Elrexfio…
The U.S. Food and Drug Administration has approved a new rapid diagnostic test to identify patients with treatment-resistant acute leukemias who may benefit from the…
PANCREATIC CANCER
Utidelone now FDA orphan drug after promising cancer trial results
Biostar Pharma’s experimental therapy utidelone has been granted orphan drug status for pancreatic cancer by the U.S. Food and Drug Administration (FDA). The…
The experimental therapy iopofosine I 131Â may improve survival outcomes in children and young adults with hard-to-treat glioma, according to new clinical trial data announced…
Recent Posts
- FDA to review glioma imaging agent, sets September decision date
- I’m taking up walking to combat the fog of ‘chemo brain’
- FDA OKs first-in-human trial of cell therapy for hard-to-treat AML
- First-of-its-kind solid tumor cell therapy prepares to debut in China
- Patients and caregivers can tap into the power of humor, too
